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Abstract
Bacterial antagonism mediated by ribosomally synthesised peptides has gained considerable attention in recent 
years because of its potential applications in the control of undesirable microbiota. These peptides, generally referred to 
as bacteriocins, are defined as a heterogeneous group of ribosomally synthesised, proteinaceous substances (with or 
without further modifications) extracellularly secreted by many Gram-positive and some Gram-negative bacteria. Their 
mode of activity is primarily bactericidal and directed against closely related strains and species. These peptides are 
nearly all cationic and very often amphyphilic, which is reflected in the fact that many of these peptides kill their target 
cells by accumulation in the membrane causing increasing permeability and loss of barrier functions . Bacteriocins have 
been explored primarily as natural food preservatives, but there is much interest in exploring the application of these 
therapeutic peptides as antimicrobial agents since many of them exhibit antimicrobial activity against various important 
human pathogens.The suitability of bacteriocins such as pharmaceuticals is explored through measures of cytotoxicity, 
effects on the natural microbiota, and in vivo efficacy in mouse models. Bacteriocins are promising therapeutic agents.
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Introduction
Antimicrobial resistance of bacteria is a pivotal health concern 
worldwide in Human, as well as Veterinary Medicine. Undoubtedly, 
the excessive and often empiric antimicrobials for the treatment of 
different clinical situations has led to changes in the bacterial ecology, 
leading to fatal consequences for public health. Scientists say that the 
community-acquired sepsis should be distinguished from nosocomial 
sepsis (nosocomial). As it is known, their differences are the main 
sources of infection, the predominant bacteria and the sensitivity to 
the antimicrobial. The process is well known and studied of bacterial 
resistance becomes larger in the hospital environment, where there 
have been very aggressive microbes that spread easily from patient 
to patient. The bacteria acquire the ability to resist the action of 
antibiotics through several mechanisms such as genetic variability, the 
modification of the permeability of the inner membrane, extraction 
of the compound and enzyme inhibition, as well as modification 
of the target ribosomal or altering the composition and content of 
glycoproteins of the bacterial wall [1]. This resistance is transferred 
between organisms of the same genus (horizontal transmission) and 
between organisms of different genus (vertical transmission). Even 
more, the fact that there is limited data on antibiotic susceptibility 
and resistance surveillance in all countries (in either, Veterinary and 
Human Medicine), must be added. Many foods of animal origin are 
often reservoirs of bacteria carrying resistance genes. These bacteria 
into the gastrointestinal tract may transfer their resistance genes to 
the intestinal microbiota being the consequence the follow resistance 
sequence transfer animal-animal, animal- human, human-human [2].
Antimicrobial Peptides 
The scientific work on bacterial antagonism-mediated by protein 
molecules was sourced on the 80´s being now a significant area of 
research, whose results are reflected in the description of a large 
family of antimicrobial substances, known as antimicrobial peptides 
(AMPs). These peptides are produced by many cell types in a variety 
of life forms found in protozoa, prokaryotes, plants and animals [3-17]. 
Some of them are produced constitutively and others are synthesized 
in response to microbial attack [4-25]. Probably one of the attractions 
has been considered that such molecules represent an ancestral defense 
mechanism still not explored [20]. It will constitute an alternative to 
today’s predicament posed by the emergence of resistance to antibiotics 
[19-23]. Among the identified proteins and peptides is a great diversity 
of primary structures, but in most cases are cationic molecules 
ribosomal synthesis-mediated [9]. These molecules, often amphiphilic 
[24], direct its action to the bacterial membrane, interacting with the 
negatively charged structures leading to its permeabilization [7-25]. 
Nowadays, its known that not only AMPs´ produce permeabilization 
of bacterial membranes, but also have other role such as inhibition 
of protein synthesis or DNA, the antitumor activity, and stimulation 
of cell proliferation or angiogenesis [25]. Target organisms of 
antimicrobial peptides are very diverse (enveloped viruses, bacteria, 
fungi, trypanosomes, protozoa, parasites and cancer cells) but they 
all have in common the possession of a negatively charged surface 
membrane, low concentration of cholesterol and high transmembrane 
electric potential [26,27]. 
There is no correlation between the activity of AMPs and its 
isoelectric point, molecular weight or length. However, it has been 
shown to possess residues Lys and Arg helps peptides to reach 
the bacterial membranes, although the mechanism involved in 
permeabilization. Two factors that determine the permeability activity 
of antimicrobial peptides are amphipathic and hydrophobicity [19]. It 
has recently been seen some AMPs insert their propellers obliquely to 
promote permeabilization membrane [28]. 
AMPs Produced by Bacteria
Antimicrobial peptides produced by bacteria are also called 
bacteriocins, and defined as “a heterogeneous group of ribosomal 
synthetic peptides with or without further modifications, which are 
secreted extracellularly and have a bactericidal mechanism of action 
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against related strains” [29,30-32]. However, that some bacteriocins in 
Gram-positive have a broader spectrum [33,34] and in some cases may 
extend beyond the borders of bacteria and include protozoa, yeasts, 
fungi, and virus [35]. Bacteriocin differ from eukaryotes antimicrobial 
peptides in the high self-toxicity showing the second, as is the case of 
defensins produced by human neutrophils that are cytotoxic at high 
concentrations to the producing cell itself [36]. AMPs from bacteria 
differ basically from traditional antibiotics in: a) molecular structure, 
b) chemicals nature, c) mode and range of action, and d) absence of 
toxicity and induced resistance mechanisms [37]. Like bacteriophages, 
the bacteriocins can specifically target a particular subset of bacterial 
strains or species. However, unlike viruses, some bacteriocins were 
found to be safe for human consumption by the Food and Drug 
Administration [38]. 
Its importance lies in the fact that these inhibitors have been 
described in virtually all lineages Domain Bacteria, and frequently 
the production of various types of bacteriocins from strains of the 
same species [30-41]. The bacteriocin family may be divided into 
two Gram-negative and Gram-positive´s bacteria main groups 
[42,43]. Bacteriocins have primarily been characterized in Gram- 
negative bacteria, in which is described the colicins produced by 
Escherichia coli [44-46], and the microcin generated by members of the 
Enterobacteriaceae family [47,48]. 
AMPs Obtained from Gram-Positive Bacteria
Bacteriocins of Gram- positive are abundant and more diverse than 
those described at the present for Gram-negatives [29-31]. The Gram- 
positive bacteriocins resemble many of the antimicrobial peptides 
produced by eukaryotes. They are generally cationic, amphiphilic, 
membrane permeabilizing peptides ranged in size from 2 to 6 kDa 
[43]. They also differ from bacteriocins of Gram-negative bacteria in 
two elementary ways according [49]. Firstly, the bacteriocins produced 
by Gram-positive bacteria are not necessarily lethal to the producing 
cell. This pivotal difference is because the transport mechanisms 
Gram-positive bacteria encode the release of the bacteriocin-toxin. 
Typically, their biosynthesis is self-regulated with specifically dedicated 
transport mechanisms facilitating release, although some employ 
the Sec-dependent export pathway [50-52]. Secondly, the Gram-
positive bacteria have evolved bacteriocin-specific regulation, whereas 
bacteriocins of Gram-negative bacteria rely solely on host regulatory 
networks [53].
The last twenty years of research has focused primarily on the study 
of bacteriocins produced by Lactic Acid Bacteria (LAB) on feasibility of 
using them as natural food preservatives in order to increase the lifetime 
and improve the hygienic quality of them. According to the structural 
and biological characteristics of LAB´s bacteriocins, [54] established 
four classes of bacteriocins, in which the first three are still recognized 
today. The discovery and characterization of new bacteriocins has 
become necessary to amend this classification, especially for class 
II [37-58]. Table 1 shows the classification of bacteriocins described 
by Diep et al. [32] and Cotter et al. [58] as follows: Class I: named 
lantibiotics, because they are post-translationally modified. These 
substances contain amino acids such as lanthionine and β-methyl 
lanthionine, and many dehydrated amino acids [59,60]. Based on the 
structural characteristics and mode of action, lantibiotics have been 
subdivided into two subgroups: A and B. Type A lantibiotics inhibit 
depolarization-sensitive cells of the cytoplasmic membrane [61,62] 
these are larger than type B lantibiotics and their size varies between 
21 and 38 amino acids. The best bacteriocin studied of Gram-positive 
bacteria [63]. Nisin has a dual mode of action: (1) They bind to lipid II, 
the main transporter of peptidoglycan subunits from the cytoplasm to 
the cell wall, and therefore prevent correct cell wall synthesis, leading 
CLASS SUBCLASS EXAMPLES REFERENCE
Class I
Lantibiotics
< 5 KDa
Ia: Cationic
linear
peptides.
Globular peptides
without 
charge or  net charge negative.
Nisin
Epidermin
Lacticin 3147
Mersacidin
[154]
[123]
[156]
[95]
Class II
Bacteriocins
heat-stable unmodified
< 10 kDa
IIa:
Anti-Listeria bacteriocins similar to pediocin.
IIb: 
Heterodimeric
Bacteriocins.
IIc:
Sec-dependent
Bacteriocins.
IId:
Bacteriocins without 
leader peptide.
IIe:
Cyclical
Bacteriocins.
IIf: Nonclustered
Bacteriocins.
Pediocin PA-1
Enterocin A
Lactacin F
Lactococcin G
Bacteriocin 31
Enterocin P
EJ97
Enterocin L50
AS-48
Circularin A
Gassericin A
Lactococcin A
Enterocin B
[11]
[52]
 [37,41,76]
[11]
Class III
Large heat-labile proteins 
(Bacteriolisins) * > 30 Kda
Helveticin J
Enterolisin A
[54]
Table 1: Classification of bacteriocins based on classifications proposed by Diep et al. [23,32,53] and Cotter et al. [58,68]. Class IV (non-protein motifs bacteriocins) is not 
included because it has not demonstrated the existence of members of this class. * It is suggested that this class is not considered as bacteriocins.
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to cell death, and (2) they employ lipid II as a docking molecule to 
initiate a process of membrane insertion and pore formation that 
leads to rapid cell death [64]. The type B lantibiotics are more globular 
secondary structure and do not exceed the 19 amino acids long. The 
type B lantibiotics works through enzyme inhibition. An example is 
the mersacidin, which interferes with cell wall biosynthesis [65]. The 
other well studied lantibiotic, Lacticin 3147, consists in two lantibiotic 
peptides that synergistically display antimicrobial activity [66,67]. 
It was shown that the dual activities could be distributed across two 
peptides: While one resembles type B lantibiotic mersacidin, which 
depolarizes the membrane, the other one is more similar to the type 
A lantibiotic class pore formers [68]. Bacteriocins of LAB class II are 
also small, ranging in size from 30 to 60 amino acids, are heat stable 
and contain no lanthionine in peptides [69]. These are further classified 
into 6 subgroups: Class IIa: are potent inhibitors of Listeria species, 
showing activity at low nanomolar concentrations. These bacteriocins 
are heat-stable and not post-translationally modified beyond the 
proteolytic removal of a leader peptide and the formation of a conserved 
N-terminal disulfide bridge (although some members contain an 
additional C-terminal disulfide bridge). The N-terminal region contains 
a characteristic YGNGV amino acid sequence, although variants with 
the alternate YGNGL sequence have been classified in class IIa. Briefly, 
class IIa bacteriocins kill susceptible bacteria by forming pores in their 
membranes. Initially, the bacteriocins are attracted by electrostatic 
interaction and then inserted in the membrane forming pores. This 
mechanism of action is dependent on a complex protein Mannose-
Phosphotransferase (MPT) found in the membranes of susceptible 
organisms, but the exact nature [70]. Class IIb bacteriocins, act forming 
pores in the membranes of their target cells and are composed of two 
proteins that function complementarily. The subgroup IIc consists of 
bacteriocins that are sec-dependent. The subgroup IId is not leader 
peptide Bacteriocins and transport systems used are typical of the 
bacteriocin (specific). The subset IIe are Cyclic Bacteriocins and 
finally the subgroup consisting of Bacteriocins IIf not clustered in 
the above classifications. Class III bacteriocins are large proteins and 
heat sensitive. The proposed additional class of bacteriocins (IV) is 
characterized by incorporating groups such as carbohydrates or lipids 
in the molecule to be active. Little is known about the structure and 
function of this class, some examples include leuconocin S [71] and 
lactocin 27 [72].
Several reports described the Enterococcus´ production of 
bacteriocins, also named enterocins. Most studies have been conducted 
on the species E. faecalis and E. faecium [73-75]. The best enterocin 
characterized from the genetics and biochemistry viewpoint is AS-48, 
which presents the most unusual feature of being a circular protein, 
having a broad spectrum of action. For this reason, Kemperman et al. 
[76] and Maqueda et al. [77], proposed to include the enterocin AS-
48 in a new class (class V) of circular bacteriocins. LAB´s bacteriocins 
enterococci have certain general characteristics [78,79]: a) can be 
readily isolated from fermented foods, are stable to the action of heat 
(up to 70-100°C 5 min), b) retain activity in a wide pH range (pH 4-8), 
c) have important biological activity on Listeria spp. and bactericidal 
activity (Listeria, Clostridium, Staphylococcus). The most notorius 
enterocins characterized are shown in Table 2. Other enterocins 
have been discovered and characterized at the present, such as AP-
CECT7121 isolated from a strain of E. faecalis recovered from corn 
silage [80]. This antimicrobial peptide have a broad spectrum of 
inhibitory activity against Gram-positive bacteria such as Listeria spp., 
other species of Enterococci, S. aureus, Streptococcus spp., Bacillus spp. 
and Clostridium spp. and some Gram-negative like E. coli and Shigella 
spp. [81,82]. It has also been reported in vivo antiparasitic activity 
[83], immunomodulation properties [84,85], antitumor action [86] 
and food biopreserver [80]. AP-CECT7121 is stable at a pH range of 
4.0-8.0. This enterocin belong to in the group II of the classification 
of [87]. When the bacteriocin AP-CECT7121 was studied against 
Gram-positive and Gram-negative a broader spectrum of inhibition 
was observed compared with other bacteriocins [31,88,89]. The fact 
that the enterocin maintain inhibitory activity at different pH from 
4 to 8, gives this potential use in fermented food which is subject to 
variations in pH during processing and maturation [90]. The action 
mechanism of this peptide would involve the formation of pores 
in the cytoplasmic membrane and the output of cellular material, 
as observed with enterocin 100 and AS-48 [91,92]. Other studies 
conducted “in vitro” showed the effectiveness of this peptide against a 
broad range of bacteria resistant Gram-positive aerobic and anaerobic 
conditions many of which were associated with multidrug resistance 
to conventional antibiotics [82]. Also the AP-CECT7121 enterocin has 
shown activity in vitro on common bacteria that produce mastitis in 
cattle [81]. Studies performed with the plasmid CECT7121 enterocin 
indicate that the plasmid contains genes encoding both its production 
and immunity. The broad spectrum of inhibitory activity, its stability 
in a wide range of pH and temperature (heat resistant, inactivation 
occurs at 15 minutes at 121°C) make the AP-CECT7121 enterocin 
is a molecule to be studied as a preservative food, as well as therapy 
of common infectious diseases refractory produced in human and 
veterinary medicine. 
Applications of Bacteriocins in Food 
A wide range of bacteriocins produced by BAL have been intensively 
Microorganism Bacteriocin Type Mass Da)(aminoacids)
E. faecalis
E. faecium
E. faecium
E. faecium
E. faecium
E. faecalis
E. mundtii
E. faecalis
E. faecium
E. faecium
E. faecalis 
E. faecalis
E. faecium
E. faecium
E. faecalis
E. faecium
E. faecalis
Cytolysin 
Enterocin A
Enterocin P
Bac 32
Bacteriocin GM-1
Bac 31
Mundticin ATO6, Mundticin KS
Enterocin SE-K4
Bacteriocin T8
Enterocin B
Enterocin 1071A, enterocin 1071B
MR10A MR10B
Enterocin L50; L50A, L50B
Enterocin Q
Enterocin EJ97
Enterocin RJ-11
AS-48 
Class I two-peptide 
Class IIa Pediocin-like
Class IIa Pediocin-like
Class IIa Pediocin-like 
Class IIa Pediocin-like
Class IIa Pediocin-like 
Class IIa Pediocin-like
Class IIa pediocin-like
Class IIa pediocin-like
Class IIa 
Class IIb two-peptide 
Class IIc, leaderless
Class IIc, leaderless
Class IIc, leaderless 
Class IIc, leaderless 
Class IIc, leaderless
Class IId circular bacteriocin 
3,458 (38), 2,032 (21)
4,829 (47)
4,493 (44)
7,998 (70)
4,630 (44)
(43)
4,287 (43)
5,356.2 (43)
5,090 (44)
5,479 (53)
4,285 (39), 3,897 (35)
5,202 (44), 5,208 (43)
5,190 (44), 5,178 (43)
3,980 (34)
5,328 (44)
5,049 (44)
7,166 (70)
Table 2: Classification of enterocins described from Nes et al., 2007.
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investigated enabling detailed chemical characterization [93]. Because 
BAL has been used for centuries to fermented foods, they are generally 
regarded as safe by the FDA (Food and Drug Administration). Nisin 
was the first bacteriocin isolated and approved in 1988 by FDA, for 
using in foods specifically to prevent the outbreak of Clostridium 
botulinum spores in cheese spread in England [94]. The use of nisin has 
a long history and is currently used as a safe food preservative in about 
48 different countries [93]. The attention of bacteriocin researchers 
were focused on the bacterium Listeria monocytogenes, the causative 
agent of listeriosis, because the frequency of outbreaks of infection 
combined with increased natural resistance of the causative agent. 
Furthermore, the study of this bacterium was interesting because of its 
ability of growing at refrigerated ion temperatures close to that used 
for traditional food preservation. This led to the isolation of a large 
number of Class IIa bacteriocins, which are highly active against L. 
monocytogenes [95]. Bacteriocins have also been used in cured meat, 
milk, cheese and soybean meal [49]. 
Pediodicin, is a class IIa bacteriocin made by lactic acid producing 
bacteria. A pediodicin producing strain has also been added to sausages 
finding a reduction in bacterial numbers approximately 10 000 times 
compared to untreated sausage number [96]. In addition, the active 
pediodicin was found in the inlays two months after cooling. Another 
example of a bacteriocin that could be used in the food industry is the 
piscicolin, a bacteriocin from another lactic acid producing bacteria 
[96]. The piscicolin has already been patented and will soon be used 
in meat products and to wash salad greens [96]. The Acidocin LCHV 
is another antimicrobial peptide produced by Lactobacillus acidophilus 
n.v. Er 317/ 402 strain Narine, probiotic bacteria widely used as a 
supplement to dairy milk [97]. A number of other bacterially derived 
AMPs are also used as food preservatives [98,99]. AP-CECT7121 is a 
peptide with potential application in the food industry, for its broad 
spectrum of antimicrobial activity, its stability to different temperatures 
and pH range [80]. A study in dry sausages was undertaken to evaluate 
its performance as biopreservative, showing good peptide activity 
against food pathogens with the advantage of not affecting the growth 
of Lactobacillus spp. [80].
One concern about the use of bacteriocins for food preservation is 
the selection of resistant strains. BAL studies have shown the generation 
of resistant strains of bacteriocin activity after having exposed the 
sensitive strain at 25 cycles of continuous growth in the presence of the 
bacteriocin [100]. Treatment with a combination of bacteriocins, such 
as nisin could theoretically reduce the incidence of resistance [101,102]. 
An additional concern is whether the resistance to a class of bacteriocin 
BAL may result in cross-resistance with other kinds of bacteriocin 
[101]. However, the diverse chemical nature of bacteriocins suggest 
different modes of action, which leads to believe that cross-resistance 
is more difficult to obtain, although, it has been reported some cross-
resistance between different bacteriocins within the class IIa [103]. 
Interestintingly, at the present there are not described disavantages of 
using of bacteriocins in food.
In Vivo Utilization of Bacteriocins and Biomedical 
Applications 
Bacteriocins have been primarily explored as natural food 
preservatives, but there is much interest in exploring the application of 
these peptides as therapeutic antimicrobial agents. Several bacteriocins 
possess antimicrobial activity against several important human 
pathogens. The use of bacteriocins in vivo has been focused on the 
introduction of probiotic bacteria in the gastrointestinal tract. Fewer 
studies have been conducted by administering the purified bacteriocin 
itself in animals. The use of probiotic strains could be beneficial as a 
prophylactic, but the use of purified bacteriocins seems to be higher 
to offset an established infection. This has been demonstrated by 
administration of PA-1 pediocin Pediococcus acidilactici UL5, a 
producer of pediocin PA-1, to mice infected with L. monocytogenes 
[104].
A major concern regarding the use of antibiotics is the effect on 
the body´s microbiota. The presence of commensal bacteria provides a 
barrier of great value for infection by opportunistic pathogens. Ideally, 
an antimicrobial agent should have specific activity on pathogenic 
bacteria with minimal impact on the natural microbiota. PA-1 
pediocin has been tested in vitro against human intestinal bacteria 
such as bifidobacteria and at the concentrations tested, no antagonistic 
activity was observed. In contrast, in similar studies, lantibiotics such 
as nisin class I A and nisin Z, showed inhibition against most of the 
Gram-positive strains tested [105,106].
Relationsip between Administration Route and Efficacy
In vivo studies in mouse model pediocin PA-1 had no effect 
on the intestinal microbiota [107] unlike conventional antibiotics 
such as penicillin and tetracycline [106]. Other studies undertaken 
in mice infected with L. monocytogenes, reported the use of two 
different routes of administration of the bacteriocin: intravenous 
[108,109] and intragastric [104]. Piscicolin 126, RV41 divercin 
recombinant (DvnRV41) and structural variants of DvnRV41 were 
administered intravenously to mice immediately before infection 
with L. monocytogenes [108,109]. Injection of both bacteriocins was 
effective in 15 minutes pre-challenge and 30 minutes after challenge. 
However, administration of 126 piscicolin 24 hours after challenge 
showed no significant reduction in the count of Listeria. Both of 
these experiments used only 2 g of purified bacteriocin. The fact that 
Listeria is an intracellular pathogen may explain the lack of sensitivity 
observed after administration of bacteriocin 24 hours after challenge 
[110]. One concern with the intravenous administration of peptides is 
the possibility of generate immune response. To corroborate the latter, 
pediocin ACH was introduced intraperitoneally in mice and rabbits 
to determine its antigenic properties, showing no effect on antibody 
response, appearing to be not immunogenic [111]. 
The intragastric administration of bacteriocins has also been 
studied on Class IIa bacteriocins, which are susceptible to common 
digestive proteases. However, IIa bacteriocins tend to be relatively 
stable to acidic conditions, and pediocin PA-1 was stable at pH 
2.5 for at least two hours [112]. The stability of bacteriocins in the 
gastrointestinal tract has been examined by passing purified pediocin 
PA-1 through an artificial system mimicking the human stomach 
and small intestine [113]. Pediocin PA-1 activity retained after 90 
minutes in artificial gastric conditions, whereas all activity was lost 
once the sample was in the duodenal compartment. It was suggested 
that pancreatin in the duodenum was responsible for cleaving the end 
of PA-1 pediocin, while a combination of pepsin and low pH may 
be responsible for the decrease of the activity observed in the gastric 
chamber [107]. However, intragastric administration of PA-1 pediocin 
has proven effective to reduce the load L. monocytogenes in a mouse 
model [104]. Moreover, different pharmacothecnic strategies for 
protecting bacteriocins have been assayed. The peptide encapsulation 
may preserve the power in the bacteriocin gastrointestinal tract, 
although this has not been reported for IIa bacteriocins. However, 
the nisin´s liposome encapsulation has shown some success in other 
studies [114,115]. Intragastric administration of PA-1 pediocin in mice 
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infected with L. monocytogenes has been examined by Dabour et al. 
[104], were 250 μg of treatment with PA-1 pediocin daily for three 
consecutive days resulted in a 2 log reduction in fecal Listeria account. 
L. monocytogenes in general comes through the epithelium barrier, 
after entering the small intestine and then extending the system of liver, 
spleen and central nervous systems [110]. This bacteriocin treatment 
was found to decrease the amount of L. monocytogenes reaching the 
liver and spleen [104].
Current and Potential Applications in Veterinary and 
Human Medicine
The lack of toxicity of bacteriocins to humans and animals and 
the activity to pathogenic bacteria became these peptides in potential 
therapeutic alternatives.
Treatment of methicillin-resistant Staphylococcus aureus 
(MRSA) and vancomycin-resistant Enterococcus faecalis 
(VRE) in pre-clinical trials
It has been demonstrated in pre-clinical trials that Mersacidin, 
a lantibiotic produced by Bacillus sp. strain HIL Y-85 54728 [116], 
inhibits in vivo the growth of MRSA strains in murine model [117]. The 
mechanism of action of mersacidin is through the inhibition of the cell 
wall synthesis, being its efficacy similar to the antibiotic vancomycin 
[118,119]. Other peptide, Lacticin 3147, which is a bacteriocin isolated 
from Lactococcus lactis subsp. Lactis also inhibits in vitro the growth of 
S. aureus, MRSA and VRE [120]. Other portential peptide named AP-
CECT7121 (bacteriocin isolated from Enterococcus faecalis CECT7121) 
[80] has shown in vitro efficacy against some strains of enterococcal 
and streptococcal, hospitalary and community-acquired methicillin-
resistant S. aureus [82]. 
Treatment of skin infections 
Mersacidin is also active against Propionibacterium acnes having a 
potential use in the treatment of acne [121-124]. Epidermin, lantibiotic 
isolated from Staphylococcus epidermidis is also effective in treating skin 
infections [123]. This peptide is active against P. acnes and Micrococcus 
flavus [121,125]. Gallidermin, lantibiotic isolated from Staphylococcus 
gallinarum, has also proven effectiveness against skin infections [123]. 
This peptide is also active against P. acnes, Staphylococcus simulans and 
Micrococcus flavus [121,125]. 
Prevention of tooth decay and gingivitis
Nisin has been included in mouthwashes as antimicrobial activity 
against bacteria that produce plaque and gingivitis [126]. Lacticin 
3147 inhibits the growth of Streptococcus mutans associated with 
dental caries [120]. Salivaricin A2 and B, isolated from Streptococcus 
salivarius inhibit bacteria associated with bad breath [127]. Mutacin 
1140, bacteriocin isolated from Streptococcus mutans is active against 
bacteria from caries [128].
Infections caused by contaminated biomedical implant 
devices
Nisin adsorbed to surfaces silanized, prevent the growth of Listeria 
monocytogenes [129]. Other study carried out on PVC tracheotomy 
tubes coated with Nisin, indicated tha Nisin prevent the colonization 
of S. aureus, S. epidermidis, and Streptococcus faecalis [130].
Upper respiratory tract infections 
Nisin inhibited the growth of S. pneumoniae associated with 
otitis media in in vivo trials [131]. Nisin may also inhibit the growth 
of P. aeruginosa when used in combination with polymyxin E and 
clarithromycin [132]. ST4SA peptide, a class II bacteriocin, showed 
efficacy against Gram-positive bacterial pathogens of the middle ear 
compared with other antimicrobial agents [133]. Bcn5 bacteriocin 
showed in vivo efficacy against Mycobacterium tuberculosis in a murine 
model of experimental infection, but it was less effective than the 
clinically used antibiotic, rifampicin [134]. Nisin F showed in vivo 
efficacy against S. aureus in the respiratory tract of immunosuppressed 
rats when administered intranasally [135].
Systemic Infections 
Pediocin PA-1 produced by Pediococcus acidilactici, is active against 
various strains of L. monocytogenes [136,137]. Furthermore, Pediocin 
PA-1 has the advantage of not inhibiting other intestinal bacteria when 
administered intragastrically, compared to Nisin A and Nisin Z [106]. 
Also, it has been domostrated that Piscicolin126 was active against 
Listeria monocytogenes in various tissues in murine model [108]. A 
similar effect has been reported for Abp118, a bacteriocin produced 
by Lactobacillus salivarius UCC118 and for Divercin V41 [109-138]. 
Nisin inhibits Clostridium botulinum [139], Clostridium tyrobutyricum 
[140] and Clostridium difficile [141]. AS-48 bacteriocin produced by 
Enterococcus faecalis, inhibits the growth of Salmonella choleraesuis 
[142]. Enterocin 012 isolated from Enterococcus gallinarum 012, 
is active against Salmonella typhimurium [143]. The peptide AP-
CECT7121 inhibits “in vitro” the growth of Clostridium perfringens 
and C. difficile [82].
Stomach ulcers 
Interestingly, it has been reported that Nisin, Lacticins A164 and 
BH5 inhibit in vitro the growth of Helicobacter pylori and therefore 
would have potential application in treating stomach ulcers [139-144]. 
However, no in vivo studies have been reported at the present.
Inflammation and allergy
It has reported that Duramycin B and C, and Cinnamycin are 
lantibiotics, which act indirectly by inhibiting phospholipase A2, 
sequestering the substrate phosphatidylethanolamine [145,146] have 
potential as anti-inflammatory drugs [126]. 
Treating high blood pressure 
Cinnamycin and Ancovenin are two lantibiotics that inhibit 
angiotensin converting enzyme [121-147], so they would have potential 
for treating high blood pressure [148].
Infections of the urogenital tract 
Subtilosin A, originally isolated from wild-type B. subtilis 168 
by [149] and recently found in B. amyloliquefaciens [150] is active 
against Gardnerella vaginalis and offers the advantage of not inhibit 
Lactobacillus part of the natural microflora in the vagina [150].
Spermicidal activity and potential contraceptive 
Nisin also showed contraceptive activity [151] and protective 
vaginal animal studies [35]. Subtilosin also showed potent spermicidal 
activity in vitro studies with human sperm [152] and also in vivo studies 
in animals [153]. 
Bovine bacterial mastitis 
Nisin is effective in the treatment of bovine mastitis, being approved 
by FDA by intramammary administration in dairy cattle [154,155]. 
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Other bacteriocins, like Lacticin 3147 have shown inhibition against 
streptococci and staphylococci causing bovine mastitis [156]. LFB112, 
bacteriocin produced by Bacillus subtilis, also inhibited the growth of S. 
aureus associated with mastitis [157]. Macedocin ST91KM, bacteriocin 
produced by Streptococcus gallolyticus subsp. macedonicus could also 
be considered an alternative in treatment of mastitis coil since this 
peptide inhibits Streptococcus agalactiae, Streptococcus dysgalactiae 
subsp. dysgalactiae, Streptococcus uberis, Staphylococcus aureus and 
Staphylococcus epidermidis, including resistant strains methicillin and 
oxacillin [158-159]. Other peptide named AP-CECT7121 has also 
shown in vitro efficacy against Staphylococcus aureus, Streptococcus 
dysgalactiae, S. uberis, S. agalactiae strains isolated from dairy cattle 
with mastitis [81].
Parasitic infections 
AP-CECT7121, bacteriocin isolated from Enterococcus faecalis 
CECT7121 showed antiparasitic activity on Toxocara canis through 
studies in vitro and in vivo mouse model of experimental infection [83-
160].
AMPS Citoxicity
Class IIa bacteriocins have been primarily explored as natural food 
preservatives, but there is much interest in exploring the application of 
these peptides as therapeutic antimicrobial agents [70]. The suitability 
of bacteriocins as pharmaceuticals is explored through determinations 
of cytotoxicity, effects on the natural microbiota, and in vivo efficacy in 
mouse models.
One advantage of bacteriocins from other antimicrobial treatments 
is their composition. These peptides are metabolized easily to amino 
acids, which also involves the disadvantage of being shorter in their 
antimicrobial activity. In vitro cytotoxicity studies with bacteriocins 
have been made. The Cytotoxicity of PA-1 pediocin was tested against 
simian virus 40-transfected Human colon cells and Vero monkey 
kidney cells [161], showing cytotoxic effects in both cell lines, with a 
dose of bacteriocin 700 AU / ml (probably about 10-20 mg / ml) caused 
a greater reduction 50% viable cell counts. Lower doses also affected 
the viable cell count, although this was not so dramatic. However, 
combinations of carnobacteriocins BM1 and B2 at concentrations 
100 times greater than required for antimicrobial activity showed no 
significant cytotoxic effects on human intestinal cell line Caco-2 [162]. 
The means of production and purification of bacteriocins should 
also be considered in toxicity studies. As with all antibiotic therapy, 
development of resistance to bacteriocins in bacterial pathogens is a 
critical issue to consider. This topic has been the subject of a recent 
review of Kaur et al. [163]. Of particular concern is that cross-resistance 
has been observed for the bacteriocins of different classes. For example, 
a strain of L. monocytogenes have shown resistance to Nisin, Pediocin 
PA-1, and S Leuconocin, bacteriocins of three separate classes [164]. 
On this basis, the possibility of using multiple bacteriocins to overcome 
resistant strains may not be entirely feasible. Like other antibiotics, 
bacteriocins need to be used with caution in order to minimize the 
spread of resistance phenotypes. 
At the present, scarce “in vivo” studies had been focused on 
characterize the side effects of the bacteriocins. The short proteases-
mediated half life of bacteriocins, which imply its fast degradation, 
thought the possibility that bacteriocins may have lesser side effects 
than conventional antibiotics.
Conclusions
Bacteriocins are a promising substitute for conventional antibiotics 
for several reasons. Its narrow spectrum towards restricted target 
specificity (peptides target-design) of some bacteriocins minimizes 
their impact on commensal microbiota and may decrease the threat 
of opportunistic pathogens. Furthermore, most bacteriocins are active 
at lower concentrations, and their degradation products are easily 
metabolized by the body whith probably, lesser side effects compared 
with conventional antibiotics. With the development of resistance 
to many important antibiotics, another tool for fighting bacteria is 
invaluable. 
Much of the research on bacteriocins has focused on their 
application for food preservation. Bacteriocins are active against 
several important human pathogens. Perhaps most promising is their 
activity against the foodborne pathogen Listeria monocytogenes, the 
deadliest bacterial source of food poisoning. Up to 30% of foodborne 
infections by L. monocytogenes in high-risk individuals are fatal. 
Other bacterial foodborne pathogens inhibited by some bacteriocins 
include Bacillus cereus, Clostridium botulinum, and C. perfringens. 
Beyond foodborne pathogens, bacteriocins are also active against 
other human pathogens, such as vancomycin-resistant enterococci and 
the opportunistic pathogen Staphylococcus aureus. Bacteriocins also 
show other potentially therapeutic properties as antineoplastic and 
antiviral agents. Although relatively little has been published on the 
use of bacteriocins in vivo to control bacterial infection, what is known 
is promising. Preliminary experiments have shown that some of these 
bacteriocins are effective in fighting infection by L. monocytogenes 
in mouse models. Now more is known about the mode of action of 
bacteriocins, and bacteriocins attempts engineering more power 
and stability have been successful. The application of bacteriocins as 
therapeutic agents is a rapidly developing area, and much remains to 
investigate.
References
1. Hellinger WC (2000) Confronting the problem of increasing antibiotic resistance. 
South Med J 93: 842-848.
2. Sparo M, Urbizu L, Solana MV, Pourcel G, Delpech G, et al. (2012) High-level 
resistance to gentamicin: genetic transfer between Enterococcus faecalis 
isolated from food of animal origin and human microbiota. Lett Appl Microbiol 
54: 119-125.
3. Cammue BPA, De Bolle MFC, Schoffs HME, Terras FRG, Thevissen K, et al. 
(1994) Gene encoded antimicrobial peptides from plants. (eds) Antimicrobial 
peptides. Wiley, NewYork, 91-106.
4. Sahl HG (1994) Gene-encoded antibiotics made in bacteria. (eds) Antimicrobial 
peptides. Wiley, New York, 27-53.
5. Boman HG (1995) Peptide antibiotics and their role in innate immunity. Annu 
Rev Immunol 13: 61-92.
6. Charlet M, Chernysh S, Philippe H, Hetru C, Hoffmann JA, et al. (1996) Innate 
immunity. Isolation of several cysteine-rich antimicrobial peptides from the 
blood of a mollusc, Mytilus edulis. J Biol Chem 271: 21808-21813.
7. Nissen-Meyer J and Nes IF (1997) Ribosomally synthesized antimicrobial 
peptides: their function, structure, biogenesis and mechanism of action. Arch 
Microbiol 167: 67-77.
8. García-Olmedo F, Molina A, Alamillo JM, Rodríguez-Palenzuéla P (1998) Plant 
defense peptides. Biopolymers 47: 479-491.
9. Epand RM, Vogel HJ (1999) Diversity of antimicrobial peptides and their 
mechanisms of action. Biochim Biophys Acta 1462: 11-28.
10. Leippe M (1999) Antimicrobial and cytolytic polypeptides of amoeboid protozoa-
-effector molecules of primitive phagocytes. Dev Comp Immunol 23: 267-279.
11. Nes IF, Holo H, Fimland G, Hauge HH, Nissen-Meyer J (2002) Unmodified 
peptide bacteriocins produced by lactic acid bacteria. eds. Peptide Antibiotics: 
Discovery, Mode of Actions, and Applications. New York: Marcel Dekker, 81-
117.
12. Pag U and Sahl HG (2002) Lanthionine-containing bacterial peptides. eds. 
Citation: Urbizu L, Sparo M, Sánchez Bruni S (2013) Bacterial Antagonist Mediated Protein Molecules. Clin Exp Pharmacol 3: 123. doi:10.4172/2161-
1459.1000123
Page  7 of 10
Volume 3 • Issue 2 • 1000123
Clin Exp Pharmacol
ISSN: 2161-1459 CPECR, an open access journal
Peptide Antibiotics: Discovery, Mode of Actions, and Applications. New York: 
Marcel Dekker, 47-80.
13. Zasloff M (2002) Antimicrobial peptides of multicellular organisms. Nature 415: 
389-395.
14. Ganz T (2003) Defensins: antimicrobial peptides of innate immunity. Nat Rev 
Immunol 3: 710-720.
15. Papagianni M (2003) Ribosomally synthesized peptides with antimicrobial 
properties: biosynthesis, structure, function, and applications. Biotechnol Adv 
21: 465-499.
16. Bulet P, Stöcklin R, Menin L (2004) Anti-microbial peptides: from invertebrates 
to vertebrates. Immunol Rev 198: 169-184.
17. Brogden KA (2005) Antimicrobial peptides: pore formers or metabolic inhibitors 
in bacteria? Nat Rev Microbiol 3: 238-250.
18. Gallo RL, Murakami M, Ohtake T, Zaiou M (2002) Biology and clinical relevance 
of naturally occurring antimicrobial peptides. J Allergy Clin Immunol 110: 823-
831.
19. Dennison SR, Wallace J, Harris F, Phoenix DA (2005a) Amphiphilic a-Helical 
Antimicrobial Peptides and Their Structure/Function Relationships. Prot Pept 
Letters 12: 27-29.
20. Maxwell AI, Morrison GM, Dorin JR (2003) Rapid sequence divergence in 
mammalian beta-defensins by adaptive evolution. Mol Immunol 40: 413-421.
21. Bachere E (2003) Anti-infectious immune effectors in marine invertebrates: 
Potential tools for disease control in larviculture. Aquaculture 227: 427-438.
22. Thomma BP, Cammue BP, Thevissen K (2003) Mode of action of plant 
defensins suggests therapeutic potential. Curr Drug Targets Infect Disord 3: 
1-8.
23. Nes IF, Diep DB, Holo H (2007) Bacteriocin diversity in Streptococcus and 
Enterococcus. J Bacteriol 189: 1189-1198.
24. Hancock RE, Diamond G (2000) The role of cationic antimicrobial peptides in 
innate host defences. Trends Microbiol 8: 402-410.
25. Kamysz W, OkrÃ³j M, Å ukasiak J (2003) Novel properties of antimicrobial 
peptides. Acta Biochim Pol 50: 461-469.
26. Hancock RE (1997) Peptide antibiotics. Lancet 349: 418-422.
27. Hancock REW and Chapple DS (1999) Peptide antibiotics. Antimicrobial 
Agents and Chemotherapy 43: 317-323.
28. Dennison SR, Harris F, Phoenix DA (2005) Are oblique orientated alpha-
helices used by antimicrobial peptides for membrane invasion? Protein Pept 
Lett 12: 27-29.
29. Tagg JR, Dajani AS, Wannamaker LW (1976) Bacteriocins of gram-positive 
bacteria. Bacteriol Rev 40: 722-756.
30. Tagg JR (1992) Bacteriocins of Gram-positive bacteria: an opinión regarding 
their nature, nomenclature and numbers. Bacteriocins, microcins and 
lantibiotics. Nato Asi Series, H5. 65: 33-35.
31. Jack RW, Tagg JR, Ray B (1995) Bacteriocins of gram-positive bacteria. 
Microbiol Rev 59: 171-200.
32. Diep DB, Nes IF (2002) Ribosomally synthesized antibacterial peptides in 
Gram positive bacteria. Curr Drug Targets 3: 107-122.
33. Line JE, Svetoch EA, Eruslanov BV, Perelygin VV, Mitsevich EV, et al. 
(2008) Isolation and purification of enterocin E-760 with broad antimicrobial 
activity against gram-positive and gram-negative bacteria. Antimicrob Agents 
Chemother 52: 1094-1100.
34. Svetoch EA, Eruslanov BV, Perelygin VV, Mitsevich EV, Mitsevich IP, et 
al. (2008) Diverse antimicrobial killing by Enterococcus faecium E 50-52 
bacteriocin. J Agric Food Chem 56: 1942-1948.
35. Reddy KV, Aranha C, Gupta SM, Yedery RD (2004) Evaluation of antimicrobial 
peptide nisin as a safe vaginal contraceptive agent in rabbits: in vitro and in vivo 
studies. Reproduction 128: 117-126.
36. Higazi AA, Ganz T, Kariko K, Cines DB (1996) Defensin modulates tissue-type 
plasminogen activator and plasminogen binding to fibrin and endothelial cells. 
J Biol Chem 271: 17650-17655.
37. Cleveland J, Montville TJ, Nes IF, Chikindas ML (2001) Bacteriocins: safe, 
natural antimicrobials for food preservation. Int J Food Microbiol 71: 1-20.
38. Gillor O, Etzion A, Riley MA (2008) The dual role of bacteriocins as anti- and 
probiotics. Appl Microbiol Biotechnol 81: 591-606.
39. Gálvez A (1987) Purificación, caracterización y actividad biológica de una 
sustancia antibacteriana de amplio espectro producida por Streptococcus 
faecalis subsp. liquefaciens S-48. Tesis Doctoral. Universidad de Granada.
40. Riley MA, Gordon DM (1992) A survey of Col plasmids in natural isolates of 
Escherichia coli and an investigation into the stability of Col-plasmid lineages. 
J Gen Microbiol 138: 1345-1352.
41. Maqueda M, Gálvez A, Martínez-Bueno M, Valdivia E (1998) Widespread 
production of AS-48-like bacteriocins in strains of Enterococcus faecalis? Mol 
Microbiol 29: 1318-1319.
42. Gordon DM, Oliver E, Littlefield-Wyer J (2007) The diversity of bacteriocins in 
Gram-negative bacteria. Bacteriocins: ecology and evolution. Springer; Berlin 
5-18.
43. Heng NCK, Wescombe PA, Burton JP, Jack RW, Tagg JR (2007) The diversity 
of bacteriocins in Gram-positive bacteria. Bacteriocins: ecology and evolution. 
Springer; Berlin 45-92.
44. Gratia J (1925) Sur un remarquable exemple d’antagonisme entre deux 
souches de colibacille. Comp. Rend. Soc Biol 93: 1040-1041.
45. Asensio C, Pérez-Díaz JC (1976) A new family of low molecular weight 
antibiotics from enterobacteria. Biochem Biophys Res Commun 69: 7-14.
46. Konisky J (1982) Colicins and other bacteriocins with established modes of 
action. Annu Rev Microbiol 36: 125-144.
47. Baquero F and Moreno F (1984) The microcins. FEMS Microbiol Lett 23: 117-
124.
48. Fath MJ, Zhang LH, Rush J, Kolter R (1994) Purification and characterization 
of colicin V from Escherichia coli culture supernatants. Biochemistry 33: 6911-
6917.
49. Riley MA, Wertz JE (2002) Bacteriocins: evolution, ecology, and application. 
Annu Rev Microbiol 56: 117-137.
50. Drider D, Fimland G, Héchard Y, McMullen LM, Prévost H (2006) The 
continuing story of class IIa bacteriocins. Microbiol Mol Biol Rev 70: 564-582.
51. Eijsink VG, Axelsson L, Diep DB, Håvarstein LS, Holo H, et al. (2002) Production 
of class II bacteriocins by lactic acid bacteria; an example of biological warfare 
and communication. Antonie Van Leeuwenhoek 81: 639-654.
52. Maqueda M, Sánchez-Hidalgo M, Fernández M, Montalbán-López M, Valdivia 
E, et al. (2008) Genetic features of circular bacteriocins produced by Gram-
positive bacteria. FEMS Microbiol Rev 32: 2-22.
53. Nes IF, Diep DB, Håvarstein LS, Brurberg MB, Eijsink V, et al. (1996) 
Biosynthesis of bacteriocins in lactic acid bacteria. Antonie Van Leeuwenhoek 
70: 113-128.
54. Klaenhammer TR (1993) Genetics of bacteriocins produced by lactic acid 
bacteria. FEMS Microbiol Rev 12: 39-85.
55. Franz CM, Holzapfel WH, Stiles ME (1999) Enterococci at the crossroads of 
food safety? Int J Food Microbiol 47: 1-24.
56. van Belkum MJ, Stiles ME (2000) Nonlantibiotic antibacterial peptides from 
lactic acid bacteria. Nat Prod Rep 17: 323-335.
57. Ross RP, Morgan S, Hill C (2002) Preservation and fermentation: past, present 
and future. Int J Food Microbiol 79: 3-16.
58. Cotter PD, Hill C, Ross RP (2005) Bacteriocins: developing innate immunity for 
food. Nat Rev Microbiol 3: 777-788.
59. Sahl HG, Bierbaum G (1998) Lantibiotics: biosynthesis and biological activities 
of uniquely modified peptides from gram-positive bacteria. Annu Rev Microbiol 
52: 41-79.
60. Guder A, Wiedemann I, Sahl HG (2000) Posttranslationally modified 
bacteriocins--the lantibiotics. Biopolymers 55: 62-73.
61. van Belkum MJ, Hayema BJ, Geis A, Kok J, Venema G (1989) Cloning of 
two bacteriocin genes from a lactococcal bacteriocin plasmid. Appl Environ 
Microbiol 55: 1187-1191.
62. Schüller F, Benz R, Sahl HG (1989) The peptide antibiotic subtilin acts by 
formation of voltage-dependent multi-state pores in bacterial and artificial 
membranes. Eur J Biochem 182: 181-186.
Citation: Urbizu L, Sparo M, Sánchez Bruni S (2013) Bacterial Antagonist Mediated Protein Molecules. Clin Exp Pharmacol 3: 123. doi:10.4172/2161-
1459.1000123
Page  8 of 10
Volume 3 • Issue 2 • 1000123
Clin Exp Pharmacol
ISSN: 2161-1459 CPECR, an open access journal
63. Gross E, Morell JL (1971) The structure of nisin. J Am Chem Soc 93: 4634-
4635.
64. Wiedemann I, Breukink E, van Kraaij C, Kuipers OP, Bierbaum G, et al. (2001) 
Specific binding of nisin to the peptidoglycan precursor lipid II combines pore 
formation and inhibition of cell wall biosynthesis for potent antibiotic activity. J 
Biol Chem 276: 1772-1779.
65. Brötz H, Bierbaum G, Markus A, Molitor E, Sahl HG (1995) Mode of action of 
the lantibiotic mersacidin: inhibition of peptidoglycan biosynthesis via a novel 
mechanism? Antimicrob Agents Chemother 39: 714-719.
66. Ryan MP, Meaney WJ, Ross RP, Hill C (1998) Evaluation of lacticin 3147 and 
a teat seal containing this bacteriocin for inhibition of mastitis pathogens. Appl 
Environ Microbiol 64: 2287-2290.
67. Wiedemann I, Böttiger T, Bonelli RR, Schneider T, Sahl HG, et al. (2006) 
Lipid II-based antimicrobial activity of the lantibiotic plantaricin C. Appl Environ 
Microbiol 72: 2809-2814.
68. Martin NI, Sprules T, Carpenter MR, Cotter PD, Hill C, et al. (2004) Structural 
characterization of lacticin 3147, a two-peptide lantibiotic with synergistic 
activity. Biochemistry 43: 3049-3056.
69. Klaenhammer TR (1988) Bacteriocins of lactic acid bacteria. Biochimie 70: 
337-349.
70. Lohans CT, Vederas JC (2012) Development of Class IIa Bacteriocins as 
Therapeutic Agents. Int J Microbiol 2012: 386410.
71. Bruno ME, Montville TJ (1993) Common mechanistic action of bacteriocins 
from lactic Acid bacteria. Appl Environ Microbiol 59: 3003-3010.
72. Upreti GC, Hinsdill RD (1975) Production and mode of action of lactocin 
27: bacteriocin from a homofermentative Lactobacillus. Antimicrob Agents 
Chemother 7: 139-145.
73. Park SH, Itoh K, Fujisawa T (2003) Characteristics and identification of 
enterocins produced by Enterococcus faecium JCM 5804T. J Appl Microbiol 
95: 294-300.
74. De Vuyst L, Foulquié Moreno MR, Revets H (2003) Screening for enterocins 
and detection of hemolysin and vancomycin resistance in enterococci of 
different origins. Int J Food Microbiol 84: 299-318.
75. Foulquié Moreno MR, Sarantinopoulos P, Tsakalidou E, De Vuyst L (2006) 
The role and application of enterococci in food and health. Int J Food Microbiol 
106: 1-24.
76. Kemperman R, Kuipers A, Karsens H, Nauta A, Kuipers O, et al. (2003) 
Identification and characterization of two novel clostridial bacteriocins, circularin 
A and closticin 574. Appl Environ Microbiol 69: 1589-1597.
77. Maqueda M, Gálvez A, Bueno MM, Sanchez-Barrena MJ, González C, et al. 
(2004) Peptide AS-48: prototype of a new class of cyclic bacteriocins. Curr 
Protein Pept Sci 5: 399-416.
78. Giraffa G (1995) Enterococcal bacteriocins: their potential use as anti Listeria 
factors in dairy technology. Food Microbiol 12: 291-299.
79. Foulquié Moreno MR, Callewaert R, Devreese B, Van Beeumen J, De Vuyst 
L (2003) Isolation and biochemical characterisation of enterocins produced by 
enterococci from different sources. J Appl Microbiol 94: 214-229.
80. Sparo M, Nuñez GG, Castro M, Calcagno ML, García Allende MA, et al. (2008) 
Characteristics of an environmental strain, Enterococcus faecalis CECT7121, 
and its effects as additive on craft dry-fermented sausages. Food Microbiol 25: 
607-615.
81. Sparo MD, Jones DG, Sánchez Bruni SF (2009) In vitro efficacy of the novel 
peptide CECT7121 against bacteria isolated from mastitic dairy cattle. Lett Appl 
Microbiol 48: 187-192.
82. Sparo MD, Jones DG, Sánchez Bruni SF (2009) Assessment of the in vitro 
efficacy of the novel antimicrobial peptide CECT7121 against human Gram-
positive bacteria from serious infections refractory to treatment. Chemotherapy 
55: 270-277.
83. Basualdo J, Sparo M, Chiodo P, Ciarmela M, Minvielle M (2007) Oral treatment 
with a potential probiotic (Enterococcus faecalis CECT 7121) appears to 
reduce the parasite burden of mice infected with Toxocara canis. Ann Trop 
Med Parasitol 101: 559-562.
84. Castro M, Sparo MD, Molina M, Andino J, Manghi M (2008a) Enterococcus 
faecalis CECT7121 induces systemic immunomodulatory effects and protects 
from Salmonella infection. Int J Prob Preb 2: 215-224.
85. Castro M, Molina M, Sparo M, Manghi M (2008b) Effects of Enterococcus 
faecalis CECT7121 on the specific immune response after dtpw vaccination. 
Int J Prob Preb. 3: 25-30.
86. Di Sciullo P, Castro M, Molina M, Sparo M, Mongini C, Manghi M (2006) 
Efecto Antiproliferativo De Enterococcus faecalis CECT7121 Sobre Células 
Del Linfoma T MURINO LBC. LIV Reunión Anual Sociedad Argentina de 
Inmunología, LI Reunión Sociedad Argentina de Investigación Clínica. Mar del 
Plata, 8 y el 11 de noviembre de 2006.
87. Héchard Y, Sahl HG (2002) Mode of action of modified and unmodified 
bacteriocins from Gram-positive bacteria. Biochimie 84: 545-557.
88. Balla E, Dicks LM, Du Toit M, Van Der Merwe MJ, Holzapfel WH (2000) 
Characterization and cloning of the genes encoding enterocin 1071A and 
enterocin 1071B, two antimicrobial peptides produced by Enterococcus 
faecalis BFE 1071. Appl Environ Microbiol 66: 1298-1304.
89. Zhu WM, Liu W, Wu DQ (2000) Isolation and characterization of a new 
bacteriocin from Lactobacillus gasseri KT7. J Appl Microbiol 88: 877-886.
90. Foulquié Moreno MR, Rea MC, Cogan TM, De Vuyst L (2003) Applicability 
of a bacteriocin-producing Enterococcus faecium as a co-culture in Cheddar 
cheese manufacture. Int J Food Microbiol 81: 73-84.
91. Kato T, Matsuda T, Yoneyama Y, Kato H, Nakamura R (1993) Isolation of 
Enterococcus faecium with antibacterial activity and characterization of its 
bacteriocin. Biosci Biotechnol Biochem 57: 551-556.
92. Mendoza F, Maqueda M, Gálvez A, Martínez-Bueno M, Valdivia E (1999) 
Antilisterial activity of peptide AS-48 and study of changes induced in the cell 
envelope properties of an AS-48-adapted strain of Listeria monocytogenes. 
Appl Environ Microbiol 65: 618-625.
93. Ross RP, Galvin M, McAuliffe O, Morgan SM, Ryan MP, et al. (1999) Developing 
applications for lactococcal bacteriocins. Antonie Van Leeuwenhoek 76: 337-
346.
94. Chung KT, Dickson JS, Crouse JD (1989) Effects of nisin on growth of bacteria 
attached to meat. Appl Environ Microbiol 55: 1329-1333.
95. Ennahar S, Sashihara T, Sonomoto K, Ishizaki A (2000) Class IIa bacteriocins: 
biosynthesis, structure and activity. FEMS Microbiol Rev 24: 85-106.
96. Raloff J (1998) Staging germ warfare in foods. Sci News 153: 89-90.
97. Mkrtchyan H, Gibbons S, Heidelberger S, Zloh M, Limaki HK (2010) Purification, 
characterisation and identification of acidocin LCHV, an antimicrobial peptide 
produced by Lactobacillus acidophilus n.v. Er 317/402 strain Narine. Int J 
Antimicrob Agents 35: 255-260.
98. Gálvez A, Abriouel H, López RL, Ben Omar N (2007) Bacteriocin-based 
strategies for food biopreservation. Int J Food Microbiol 120: 51-70.
99. Chen H and Hoover DG (2003) Bacteriocins and their food aplications. Comp 
Rev Food Sci Food Saf 2: 82-100.
100. Dykes GA, Hastings JW (1998) Fitness costs associated with class IIa 
bacteriocin resistance in Listeria monocytogenes B73. Lett Appl Microbiol 26: 
5-8.
101. Bouttefroy A and Milliere J (2000) Nisin-curvaticin 13 combinations for 
avoiding the regrowth of bacteriocin resistant cells of bacteriocin resistant 
cells of Listeria monocytogenes ATCC 15313. Int J Food Microbiol 62: 65-75.
102. Vignolo G, Palacios J, Farías ME, Sesma F, Schillinger U, et al. (2000) 
Combined effect of bacteriocins on the survival of various Listeria species in 
broth and meat system. Curr Microbiol 41: 410-416.
103. Rekhif N, Atrih A, Lefebvre G (1994) Selection and properties of spontaneous 
mutants of Listeria monocytogenes ATCC 15313 resistant to different 
bacteriocins produced by lactic acid bacteria strains. Current Microbiol 28: 
237-241.
104. Dabour N, Zihler A, Kheadr E, Lacroix C, Fliss I (2009) In vivo study on the 
effectiveness of pediocin PA-1 and Pediococcus acidilactici UL5 at inhibiting 
Listeria monocytogenes. Int J Food Microbiol 133: 225-233.
105. Kheadr E, Bernoussi N, Lacroix C, Fliss I. (2004) “Comparison of the sensitivity 
of commercial strains and infant isolates of bifidobacteria to antibiotics and 
bacteriocins” Int Dairy J 14: 1041-1053.
106. Le Blay G, Lacroix C, Zihler A, Fliss I (2007) In vitro inhibition activity of nisin 
A, nisin Z, pediocin PA-1 and antibiotics against common intestinal bacteria. 
Lett Appl Microbiol 45: 252-257.
Citation: Urbizu L, Sparo M, Sánchez Bruni S (2013) Bacterial Antagonist Mediated Protein Molecules. Clin Exp Pharmacol 3: 123. doi:10.4172/2161-
1459.1000123
Page  9 of 10
Volume 3 • Issue 2 • 1000123
Clin Exp Pharmacol
ISSN: 2161-1459 CPECR, an open access journal
107. Bernbom N, Jelle B, Brogren CH, Vogensen FK, Nørrung B, et al. (2009) 
Pediocin PA-1 and a pediocin producing Lactobacillus plantarum strain do not 
change the HMA rat microbiota. Int J Food Microbiol 130: 251-257.
108. Ingham A, Ford M, Moore RJ, Tizard M (2003) The bacteriocin piscicolin 126 
retains antilisterial activity in vivo. J Antimicrob Chemother 51: 1365-1371.
109. Rihakova J, Cappelier JM, Hue I, Demnerova K, Fédérighi M, et al. (2010) In 
vivo activities of recombinant divercin V41 and its structural variants against 
Listeria monocytogenes. Antimicrob Agents Chemother 54: 563-564.
110. Ramaswamy V, Cresence VM, Rejitha JS, Lekshmi MU, Dharsana KS, et 
al. (2007) Listeria--review of epidemiology and pathogenesis. J Microbiol 
Immunol Infect 40: 4-13.
111. Bhunia AK, Johnson MC, Ray B, Belden EL (1990) Antigenic property of 
pediocin AcH produced by Pediococcus acidilactici H. J Appl Bacteriol 69: 
211-215.
112. Bhunia AK, Johnson MC, Ray B (1988) Purification, characterization and 
antimicrobial spectrum of a bacteriocin produced by Pediococcus acidilactici. 
J Appl Bacteriol 65: 261-268.
113. Kheadr E, Zihler A, Dabour N, Lacroix C, Le Blay G, et al. (2010) Study of 
the physicochemical and biological stability of pediocin PA-1 in the upper 
gastrointestinal tract conditions using a dynamic in vitro model. J Appl 
Microbiol 109: 54-64.
114. Benech RO, Kheadr EE, Laridi R, Lacroix C, Fliss I (2002) Inhibition of Listeria 
innocua in cheddar cheese by addition of nisin Z in liposomes or by in situ 
production in mixed culture. Appl Environ Microbiol 68: 3683-3690.
115. Were LM, Bruce B, Davidson PM, Weiss J (2004) Encapsulation of nisin and 
lysozyme in liposomes enhances efficacy against Listeria monocytogenes. J 
Food Prot 67: 922-927.
116. Sass P, Jansen A, Szekat C, Sass V, Sahl HG, et al. (2008) The lantibiotic 
mersacidin is a strong inducer of the cell wall stress response of Staphylococcus 
aureus. BMC Microbiol 8: 186.
117. Kruszewska D, Sahl HG, Bierbaum G, Pag U, Hynes SO, et al. (2004) 
Mersacidin eradicates methicillin-resistant Staphylococcus aureus (MRSA) in 
a mouse rhinitis model. J Antimicrob Chemother 54: 648-653.
118. Chatterjee S, Chatterjee DK, Jani RH, Blumbach J, Ganguli BN, et al. (1992) 
Mersacidin, a new antibiotic from Bacillus. In vitro and in vivo antibacterial 
activity. J Antibiot (Tokyo) 45: 839-845.
119. Limbert M, Isert D, Klesel N, Markus A, Seibert G, et al. (1991) 
Chemotherapeutic properties of mersacidin in vitro and in vivo. (eds) Nisin 
and novel lantibiotics. ESCOM, Leiden, The Netherlands.
120. Galvin M, Hill C, Ross RP (1999) Lacticin 3147 displays activity in buffer against 
gram-positive bacterial pathogens which appear insensitive in standard plate 
assays. Lett Appl Microbiol 28: 355-358.
121. Jung G (1991a) Lantibiotics-ribosomally synthesized biologically active 
polypeptides containing sulfide bridges and a, B-didehydroamino acids. 
Angew Chem Int Ed Engl 30: 1051-1068.
122. Jung G (1991b) Lantibiotics: a survey. In: Jung G, Sahl HG (eds) Nisin and 
novel lantibiotics. ESCOM Science Publishers, Leiden, The Netherlands, 1-34.
123. Kellner R, Jung G, Hörner T, Zähner H, Schnell N, et al. (1988) Gallidermin: a 
new lanthionine-containing polypeptide antibiotic. Eur J Biochem 177: 53-59.
124. Niu WW, Neu HC (1991) Activity of mersacidin, a novel peptide, compared 
with that of vancomycin, teicoplanin, and daptomycin. Antimicrob Agents 
Chemother 35: 998-1000.
125. Bonelli R, Wiedemann RI, Sahl HG (2006) Lantibiotics. In: Kastin A (ed) 
Handbook of biologically active peptides. Elsevier, New York, NY.
126. van Kraaij C, de Vos WM, Siezen RJ, Kuipers OP (1999) Lantibiotics: 
biosynthesis, mode of action and applications. Nat Prod Rep 16: 575-587.
127. Tagg JR (2004) Prevention of streptococcal pharyngitis by anti-Streptococcus 
pyogenes bacteriocin-like inhibitory substances (BLIS) produced by 
Streptococcus salivarius. Indian J Med Res 119 Suppl: 13-16.
128. Hillman JD, Novák J, Sagura E, Gutierrez JA, Brooks TA, et al. (1998) Genetic 
and biochemical analysis of mutacin 1140, a lantibiotic from Streptococcus 
mutans. Infect Immun 66: 2743-2749.
129. Bower CK, McGuire J, Daeschel MA (1995) Suppression of Listeria 
monocytogenes colonization following adsorption of nisin onto silica surfaces. 
Appl Environ Microbiol 61: 992-997.
130. Bower CK, Parker JE, Higgins AZ, Oest ME, Wilson JT, et al. (2002) Protein 
antimicrobial barriers to bacterial adhesion: in vitro and in vivo evaluation of 
nisin-treated implantable materials. Surf B: Biointerfaces 25: 81-90.
131. Goldstein BP, Wei J, Greenberg K, Novick R (1998) Activity of nisin against 
Streptococcus pneumoniae, in vitro, and in a mouse infection model. J 
Antimicrob Chemother 42: 277-278.
132. Giacometti A, Cirioni O, Barchiesi F, Fortuna M, Scalise G (1999) In-vitro 
activity of cationic peptides alone and in combination with clinically used 
antimicrobial agents against Pseudomonas aeruginosa. J Antimicrob 
Chemother 44: 641-645.
133. Knoetze H, Todorov SD, Dicks LM (2008) A class IIa peptide from Enterococcus 
mundtii inhibits bacteria associated with otitis media. Int J Antimicrob Agents 
31: 228-234.
134. Sosunov V, Mischenko V, Eruslanov B, Svetoch E, Shakina Y, et al. (2007) 
Antimycobacterial activity of bacteriocins and their complexes with liposomes. 
J Antimicrob Chemother 59: 919-925.
135. De Kwaadsteniet M, Doeschate KT, Dicks LM (2009) Nisin F in the treatment 
of respiratory tract infections caused by Staphylococcus aureus. Lett Appl 
Microbiol 48: 65-70.
136. Naghmouchi K, Drider D, Kheadr E, Lacroix C, Prévost H, et al. (2006) Multiple 
characterizations of Listeria monocytogenes sensitive and insensitive variants 
to divergicin M35, a new pediocin-like bacteriocin. J Appl Microbiol 100: 29-39.
137. Naghmouchi K, Kheadr E, Lacroix C, Fliss I (2007) Class I/Class IIa bacteriocin 
cross-resistance phenomenon in Listeria monocytogenes. Food Microbiol 24: 
718-727.
138. Corr SC, Li Y, Riedel CU, O’Toole PW, Hill C, et al. (2007) Bacteriocin 
production as a mechanism for the antiinfective activity of Lactobacillus 
salivarius UCC118. Proc Natl Acad Sci U S A 104: 7617-7621.
139. Delves-Broughton J, Blackburn P, Evans RJ, Hugenholtz J (1996) Applications 
of the bacteriocin, nisin. Antonie Van Leeuwenhoek 69: 193-202.
140. de Carvalho AA, Mantovani HC, Vanetti MC (2007) Bactericidal effect of 
bovicin HC5 and nisin against Clostridium tyrobutyricum isolated from spoiled 
mango pulp. Lett Appl Microbiol 45: 68-74.
141. Bartoloni A, Mantella A, Goldstein BP, Dei R, Benedetti M, et al. (2004) In-vitro 
activity of nisin against clinical isolates of Clostridium difficile. J Chemother 
16: 119-121.
142. Abriouel H, Valdivia E, Gálvez A, Maqueda M (1998) Response of Salmonella 
choleraesuis LT2 spheroplasts and permeabilized cells to the bacteriocin AS-
48. Appl Environ Microbiol 64: 4623-4626.
143. Jennes W, Dicks LM, Verwoerd DJ (2000) Enterocin 012, a bacteriocin 
produced by Enterococcus gallinarum isolated from the intestinal tract of 
ostrich. J Appl Microbiol 88: 349-357.
144. Kim TS, Hur JW, Yu MA, Cheigh CI, Kim KN, et al. (2003) Antagonism of 
Helicobacter pylori by bacteriocins of lactic acid bacteria. J Food Prot 66: 3-12.
145. Fredenhagen A, Fendrich G, Märki F, Märki W, Gruner J, et al. (1990) 
Duramycins B and C, two new lanthionine containing antibiotics as inhibitors of 
phospholipase A2. Structural revision of duramycin and cinnamycin. J Antibiot 
(Tokyo) 43: 1403-1412.
146. Märki F, Hänni E, Fredenhagen A, van Oostrum J (1991) Mode of action of the 
lanthionine-containing peptide antibiotics duramycin, duramycin B and C, and 
cinnamycin as indirect inhibitors of phospholipase A2. Biochem Pharmacol 
42: 2027-2035.
147. Shiba T, Wakamiya T, Fukase K, Ueki Y, Teshima T, Nishikawa M (1991) 
Structure of the lanthionine peptides nisin, ancovenin and lanthiopeptin. (eds) 
Nisin and novel lantibiotics. Escom, Leiden, The Netherlands.
148. Kido Y, Hamakado T, Yoshida T, Anno M, Motoki Y, et al. (1983) Isolation 
and characterization of ancovenin, a new inhibitor of angiotensin I converting 
enzyme, produced by actinomycetes. J Antibiot (Tokyo) 36: 1295-1299.
149. Babasaki K, Takao T, Shimonishi Y, Kurahashi K (1985) Subtilosin A, a 
new antibiotic peptide produced by Bacillus subtilis 168: isolation, structural 
analysis, and biogenesis. J Biochem 98: 585-603.
150. Sutyak KE, Wirawan RE, Aroutcheva AA, Chikindas ML (2008) Isolation of the 
Citation: Urbizu L, Sparo M, Sánchez Bruni S (2013) Bacterial Antagonist Mediated Protein Molecules. Clin Exp Pharmacol 3: 123. doi:10.4172/2161-
1459.1000123
Page  10 of 10
Volume 3 • Issue 2 • 1000123
Clin Exp Pharmacol
ISSN: 2161-1459 CPECR, an open access journal
Bacillus subtilis antimicrobial peptide subtilosin from the dairy product-derived 
Bacillus amyloliquefaciens. J Appl Microbiol 104: 1067-1074.
151. Aranha C, Gupta S, Reddy KV (2004) Contraceptive efficacy of antimicrobial 
peptide Nisin: in vitro and in vivo studies. Contraception 69: 333-338.
152. Sutyak KE, Anderson RA, Dover SE, Feathergill KA, Aroutcheva AA, et al. 
(2008) Spermicidal activity of the safe natural antimicrobial peptide subtilosin. 
Infect Dis Obstet Gynecol 2008: 540758.
153. Silkin L, Hamza S, Kaufman S, Cobb SL, Vederas JC (2008) Spermicidal 
bacteriocins: lacticin 3147 and subtilosin A. Bioorg Med Chem Lett 18: 3103-
3106.
154. Taylor I, Hirsh A, Mattick TR (1949) The treatment of bovine streptococcal and 
staphylococcal mastitis with nisin. The Vet Record 61: 197-198.
155. Broadbent JR, Chou YC, Gillies K, Kondo JK (1989) Nisin inhibits several 
gram-positive, mastitis-causing pathogens. J Dairy Sci 72: 3342-3345.
156. Ryan MP, Flynn J, Hill C, Ross RP, Meaney WJ (1999) The natural food grade 
inhibitor, lacticin 3147, reduced the incidence of mastitis after experimental 
challenge with Streptococcus dysgalactiae in nonlactating dairy cows. J Dairy 
Sci 82: 2625-2631.
157. Xie J, Zhang R, Shang C, Guo Y (2009) Isolation and characterization of a 
bacteriocin produced by an isolated Bacillus subtilis LFB112 that exhibits 
antimicrobial activity against domestic animal pathogens. Afr J Biotechnol 8: 
5611-5619.
158. Pieterse R, Todorov SD, Dicks LM (2008) Bacteriocin ST91KM, produced 
by Streptococcus gallolyticus subsp. macedonicus ST91KM, is a narrow-
spectrum peptide active against bacteria associated with mastitis in dairy 
cattle. Can J Microbiol 54: 525-531.
159. Pieterse R, Todorov S, Dicks LMT (2010) Mode of action and in vitro 
susceptibility of mastitis pathogens to macedocin ST91KM and preparation of 
a teat seal containing the bacteriocins. Braz J Microbiol 41: 133-145.
160. Chiodo PG, Sparo MD, Pezzani BC, Minvielle MC, Basualdo JA (2010) In vitro 
and in vivo effects of Enterococcus faecalis CECT7121 on Toxocara canis. 
Mem Inst Oswaldo Cruz 105: 615-620.
161. Murinda SE, Rashid KA, Roberts RF (2003) In vitro assessment of the 
cytotoxicity of nisin, pediocin, and selected colicins on simian virus 
40-transfected human colon and Vero monkey kidney cells with trypan blue 
staining viability assays. J Food Prot 66: 847-853.
162. Jasniewski J, Cailliez-Grimal C, Chevalot I, Millière JB, Revol-Junelles AM 
(2009) Interactions between two carnobacteriocins Cbn BM1 and Cbn B2 from 
Carnobacterium maltaromaticum CP5 on target bacteria and Caco-2 cells. 
Food Chem Toxicol 47: 893-897.
163. Kaur G, Malik RK, Mishra SK, Singh TP, Bhardwaj A, et al. (2011) Nisin and 
class IIa bacteriocin resistance among Listeria and other foodborne pathogens 
and spoilage bacteria. Microb Drug Resist 17: 197-205.
164. Crandall AD, Montville TJ (1998) Nisin resistance in Listeria monocytogenes 
ATCC 700302 is a complex phenotype. Appl Environ Microbiol 64: 231-237.
Submit your next manuscript and get advantages of 
OMICS Group submissions
Unique features:
User friendly/feasible website-translation of your paper to 50 world’s leading languages
Audio Version of published paper
Digital articles to share and explore
Special features:
250 Open Access Journals
20,000 editorial team
21 days rapid review process
Quality and quick editorial, review and publication processing
Indexing at PubMed (partial), Scopus, EBSCO, Index Copernicus and Google Scholar etc
Sharing Option: Social Networking Enabled
Authors, Reviewers and Editors rewarded with online Scientific Credits
Better discount for your subsequent articles
Submit your manuscript at: http://www.omicsonline.org/submission
Citation: Urbizu L, Sparo M, Sánchez Bruni S (2013) Bacterial Antagonist 
Mediated Protein Molecules. Clin Exp Pharmacol 3: 123. doi:10.4172/2161-
1459.1000123
